Advanced Cell Diagnostics

The firm's CEO said he's seeing significant growth in research applications from its RNA in-situ hybridization technology, and sees potential for its use in clinical settings.

Bio-Techne has also agreed to pay up to an additional $75 million if Advanced Cell Diagnostics achieves certain milestones.

The companies plan to combine ACD's RNAscope in situ hybridization assays with Leica's clinical advanced staining instruments to develop tissue-based diagnostics.

The company will use the financing to accelerate its entry into the research and clinical diagnostics markets and to launch new technology platforms.

Flagship Bio is using ACD's RNAscope and customizing and optimizing the technology for use in CLIA clinical trials with "several large pharmaceutical clients."

Merrimack will use RNAscope to select patients with heregulin-positive, locally advanced metastatic NSCLC for a Phase II clinical trial for the drug candidate MM-121. 

NEW YORK (GenomeWeb) – Advanced Cell Diagnostics announced today a preferred partnership agreement with Dundee, UK-based MicroMatrices to develop applications of its RNAscope technology.

NEW YORK (GenomeWeb) – Advanced Cell Dx today announced Edinburgh, Scotland-based CRO Aquila-Histoplex as the first accredited RNAscope Certified Service Provider in Europe.

NEW YORK (GenomeWeb) – A recent evaluation of FDA-approved molecular HPV screening assays from Roche, Hologic, and Qiagen has found that the three tests showed variations in which samples tested positive or negative.

NEW YORK (GenomeWeb) – Advanced Cell Diagnostics today announced it has been awarded a two-year $1.4 million grant from the National Cancer Institute to develop and validate a diagnostic test for differentiating various B-cell non-Hodgkin lymphomas from benign lymphoproliferative diseases.

Pages

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.